Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Enhanced care coordination improves HIV viral load suppression rates.

Hewitt RG, Williams D, Adule R, Feldman I, Alsumidaie M.

Am J Manag Care. 2019 Jun 1;25(6):e167-e172.

2.

Life stress and adherence to antiretroviral therapy among HIV-positive individuals: a preliminary investigation.

Bottonari KA, Roberts JE, Ciesla JA, Hewitt RG.

AIDS Patient Care STDS. 2005 Nov;19(11):719-27.

PMID:
16283832
3.

The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone.

Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ, Palic B, Schur JL, Buggé CJ, Ljungqvist A, Espinosa O, Hewitt RG.

J Clin Pharmacol. 2004 Mar;44(3):293-304.

PMID:
14973306
4.

Human immunodeficiency virus-associated nephropathy: a primary care perspective.

Olatinwo T, Hewitt RG, Venuto RC.

Arch Intern Med. 2004 Feb 9;164(3):333-6. Review.

PMID:
14769631
5.

Serum interferon inhibitor declines in patients with HIV-1 infection after a change in antiretroviral therapy.

Chadha KC, Schwartz SA, Nair MP, Demeter LR, Hewitt RG.

Immunol Invest. 2003 Nov;32(4):299-312.

PMID:
14603996
6.

Impact of human immunodeficiency virus type-1-associated cognitive dysfunction on activities of daily living and quality of life.

Benedict RH, Mezhir JJ, Walsh K, Hewitt RG.

Arch Clin Neuropsychol. 2000 Aug;15(6):535-44.

7.

Effects of didanosine formulations on the pharmacokinetics of amprenavir.

Shelton MJ, Giovanniello AA, Cloen D, Berenson CS, Keil K, DiFrancesco R, Hewitt RG.

Pharmacotherapy. 2003 Jul;23(7):835-42.

PMID:
12885096
8.

Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients.

Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S, Morse GD.

Antimicrob Agents Chemother. 2003 May;47(5):1694-9.

9.

Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity.

Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD.

J Clin Pharmacol. 2003 Feb;43(2):171-9.

PMID:
12616670
10.
11.

Abacavir hypersensitivity reaction.

Hewitt RG.

Clin Infect Dis. 2002 Apr 15;34(8):1137-42. Epub 2002 Mar 19.

PMID:
11915004
12.

Effect of cocaine on chemokine and CCR-5 gene expression by mononuclear cells from normal donors and HIV-1 infected patients.

Nair MP, Mahajan S, Chadha KC, Nair NM, Hewitt RG, Pillai SK, Chadha P, Sukumaran PC, Schwartz SA.

Adv Exp Med Biol. 2001;493:235-40. No abstract available.

PMID:
11727771
13.

The role of gender in HIV progression.

Hewitt RG, Parsa N, Gugino L.

BETA. 2001 Spring;14(1):13-6. No abstract available.

PMID:
11695332
14.
15.

Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.

Shelton MJ, Wynn HE, Hewitt RG, DiFrancesco R.

J Clin Pharmacol. 2001 Apr;41(4):435-42.

PMID:
11304900
16.

Women's health. The role of gender in HIV progression.

Hewitt RG, Parsa N, Gugino L.

AIDS Read. 2001 Jan;11(1):29-33. Review.

PMID:
11215085
17.

If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.

Shelton MJ, Mei H, Hewitt RG, Defrancesco R.

Antimicrob Agents Chemother. 2001 Jan;45(1):298-300.

18.

Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group.

Hewitt RG, Yiannoutsos CT, Higgs ES, Carey JT, Geiseler PJ, Soave R, Rosenberg R, Vazquez GJ, Wheat LJ, Fass RJ, Antoninievic Z, Walawander AL, Flanigan TP, Bender JF.

Clin Infect Dis. 2000 Oct;31(4):1084-92. Epub 2000 Oct 25.

PMID:
11049793
19.

Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients.

Shelton MJ, Akbari B, Hewitt RG, Adams JM, Morse GD.

J Acquir Immune Defic Syndr. 2000 May 1;24(1):79-82. No abstract available.

PMID:
10877501
20.

Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients.

Nair MP, Chadha KC, Hewitt RG, Mahajan S, Sweet A, Schwartz SA.

Clin Diagn Lab Immunol. 2000 Jan;7(1):96-100.

21.

Natural history of intestinal microsporidiosis among patients infected with human immunodeficiency virus.

Dascomb K, Clark R, Aberg J, Pulvirenti J, Hewitt RG, Kissinger P, Didier ES.

J Clin Microbiol. 1999 Oct;37(10):3421-2.

22.

Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease.

Hewitt RG, Papandonatos GD, Shelton MJ, Hsiao CB, Harmon BJ, Kaczmarek SR, Amsterdam D.

AIDS. 1999 Jul 30;13(11):1367-72.

PMID:
10449290
23.

Comparison of a neural network approach with five traditional methods for predicting creatinine clearance in patients with human immunodeficiency virus infection.

Herman RA, Noormohamed S, Hirankarn S, Shelton MJ, Huang E, Morse GD, Hewitt RG, Stapleton JT.

Pharmacotherapy. 1999 Jun;19(6):734-40.

PMID:
10391419
24.

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients.

Hewitt RG, Shelton MJ, Esch LD.

AIDS. 1999 May 7;13(7):868-9. No abstract available.

PMID:
10357393
25.
26.

Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients.

Adams JM, Shelton MJ, Hewitt RG, Grasela TH, DeRemer M, Morse GD.

Antimicrob Agents Chemother. 1998 Apr;42(4):821-6.

27.

Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients.

Graybill JR, Vazquez J, Darouiche RO, Morhart R, Greenspan D, Tuazon C, Wheat LJ, Carey J, Leviton I, Hewitt RG, MacGregor RR, Valenti W, Restrepo M, Moskovitz BL.

Am J Med. 1998 Jan;104(1):33-9.

PMID:
9528717
28.

Zalcitabine population pharmacokinetics: application of radioimmunoassay.

Adams JM, Shelton MJ, Hewitt RG, DeRemer M, DiFrancesco R, Grasela TH, Morse GD.

Antimicrob Agents Chemother. 1998 Feb;42(2):409-13.

29.

Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine.

Shelton MJ, Adams JM, Hewitt RG, Steinwandel C, DeRemer M, Cousins S, Morse GD.

Pharmacotherapy. 1997 May-Jun;17(3):438-44.

PMID:
9165548
30.

Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease.

Huang E, Hewitt RG, Shelton M, Morse GD.

Pharmacotherapy. 1996 Mar-Apr;16(2):222-9.

PMID:
8820465
31.

Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.

Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Poiesz B, Caligiuri MA.

Blood. 1995 Nov 1;86(9):3287-94.

32.

Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine.

Foisy MM, Slayter KL, Hewitt RG, Morse GD.

Ann Pharmacother. 1994 Sep;28(9):1025-8.

PMID:
7803875
33.

Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex.

Hewitt RG, Morse GD, Lawrence WD, Maliszewski ML, Santora J, Bartos L, Bonnem E, Poiesz B.

Antimicrob Agents Chemother. 1993 Mar;37(3):512-22.

Supplemental Content

Loading ...
Support Center